Combination of Pembrolizumab and Lenvatinib, in Pre-treated Thymic CArcinoma paTIents (PECATI)

• ClinicalTrials.gov Identifier: NCT04710628
• Recruitment Status: Recruiting
• First Posted: January 15, 2021
• Last Update Posted: January 19, 2023
• Sponsor: MedSIR
• Collaborator: Merck Sharp & Dohme LLC
• Information provided by (Responsible Party): MedSIR

Study Description

Brief Summary:

This is a multicentric, open-label, single arm phase II study to evaluate the efficacy and safety of the combination of pembrolizumab and lenvatinib in pre-treated thymic carcinoma patients who have progressed after at least one line of platinum-based chemotherapy for advanced disease without having received any previous immunotherapy (previous bevacizumab allowed, but not sunitinib), and not amenable to curative-intent radical surgery and/or radiotherapy, regardless of PD-L1 status.

Condition or disease	Intervention/treatment	Phase
Metastatic Thymic Carcinoma; Thymoma Type B3	Drug: Pembrolizumab; Drug: Lenvatinib 10 mg	Phase 2

Detailed Description:

Men and women aged ≥ 18 years old diagnosed with B3-thymoma or metastatic thymic carcinoma who have progressed after at least one line of platinum-based chemotherapy for advanced disease without having received any previous immunotherapy (previous bevacizumab allowed, but not sunitinib), and not amenable to curative-intent radical surgery and/or radiotherapy, regardless of PD- L1 status. Presence of measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) version (v.)1.1 criteria. Patients are not eligible if they are candidates for a local treatment with a curative intention. Patients must present Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1 and with adequate organ function.

Study Design

• Study Type: Interventional (Clinical Trial)
• Estimated Enrollment: 43 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: A Multicentric, Open-Label, Single Arm Phase II Study To Evaluate The Efficacy And Safety Of The Combination Of PEmbrolizumab And Lenvatinib In Pre-Treated Thymic Carcinoma PaTIents. PECATI.
• Actual Study Start Date: September 21, 2021
• Estimated Primary Completion Date: June 2023
• Estimated Study Completion Date: October 2023

Arms and Interventions

Arm

Intervention/treatment

Experimental: PEMBROLIZUMAB + LENVATINIB; Pembrolizumab 200 mg will be administered to patients as 30-minute IV infusion every 3 weeks (a window of -5 minutes and +10 minutes is permitted). Lenvatinib 20 mg (2 capsules of 10 mg) will be administered daily at the same time, with or without food. At the day 1 of each cycle, lenvatinib will be administered within 4 hours after finishing pembrolizumab (lenvatinib after pembrolizumab). Lenvatinib cannot be chewed

Drug: Pembrolizumab; Pembrolizumab 200 mg will be administered to patients as 30-minute intravenous infusion (a window of -5 minutes and +10 minutes is permitted) every 3 weeks.; Other Name: MK-3475, lambrolizumab; Drug: Lenvatinib 10 mg; Lenvatinib 20 mg (2 capsules of 10 mg) will be administered daily at the same time, with or without food. At the day 1 of each cycle, lenvatinib will be administered within 4 hours after finishing pembrolizumab (lenvatinib after pembrolizumab); Other Name: E7080

Outcome Measures

Primary Outcome Measures :

1. Progression-free survival (PFS) [ Time Frame: 5 months ]
   PFS rate at 5 months, defined as the percentage of patients with B3-Thymoma and Thymic Carcinoma without disease progression at 5 months after starting the treatment combination.

Secondary Outcome Measures :

1. Response rate (RR) [ Time Frame: 5 months ]
   RR with the treatment combination
2. Maximum tumor shrinkage (MTS) [ Time Frame: 5 months ]
   MTS with the treatment combination
3. Disease control rate (DCR) [ Time Frame: 5 months ]
   DCR with the treatment combination
4. Duration of response (DoR) [ Time Frame: 5 months ]
   DoR with the treatment combination
5. Overall survival (OS) [ Time Frame: 2 years ]
   OS
6. Incidence of Grade 3 and 4 AEs and SAEs [ Time Frame: 2 years ]
   Grade 3 and 4 AEs and serious adverse events (SAEs) will be assessed, according to the National Cancer Institute Common Terminology Criteria for Adverse Events Version 5.0 (CTCAE v.5.0), to determine the safety and tolerability of the combination.

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

Participants are eligible to be included in the study only if all of the following criteria apply:

1. Relapsed / Recurrent histologically confirmed B3-Thymoma or TC patients not amenable to curative-intent radical surgery and/or radiotherapy, regardless of PD-L1 expression.

2. Patients progress after at least one previous line of platinum-based chemotherapy for advanced disease:

   a. Patients treated with neo-adjuvant or adjuvant platinum-based chemotherapy combined with radical surgery or as part of radical chemo-radiotherapy are eligible if chemotherapy was completed within 6 months before enrollment.

3. Negative result for Myasthenia Gravis (MG) by acetylcholine receptor antibodies test.
4. Male/female who are at least 18 years of age on the day of signing informed consent.
5. ECOG performance status 0-1
6. Life expectancy ≥ 3 months
7. Radiological progression documented per RECIST 1.1 during or after completion of previous line therapy, per investigator's criteria.

8. Presence of measurable disease according to RECIST criteria. Lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions.

   a. Disease status must be documented by full chest and upper abdomen (including adrenal glands) CT and/or MRI within 28 days prior study enrollment. If clinically indicated, brain imaging must be performed;

9. Provides historical (obtained archived FFPE) or fresh tumor biopsy specimen for biomarker studies, if feasible. Archival tumor tissue sample or newly obtained core or excisional biopsy of a tumor lesion not previously irradiated is acceptable. Formalin-fixed, paraffin embedded (FFPE) tissue blocks are preferred to slides. Newly obtained biopsies are preferred to archival tissue. Note: If submitting unstained cut slides, newly cut slides should be submitted to the testing laboratory within 14 days from the date slides are cut.

10. A female participant is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies:

    1. Not a woman of childbearing potential (WOCBP) OR
    2. A WOCBP who agrees to follow the contraceptive guidance during the treatment period and for at least 6 months after the last dose of study treatment.
11. Has adequate bone marrow and organ function. Specimens must be collected within 10 days prior to the start of study treatment.
12. Written informed consent prior to beginning specific protocol procedures.

Exclusion Criteria:

Participants are excluded from the study if any of the following criteria apply:

1. Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti PD L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g., CTLA-4, OX 40, CD137).
2. Has received prior therapy with sunitinib.
3. Any evidence of active central nervous system (CNS) metastases and/or carcinomatous meningitis. Patients with previously treated brain metastases may participate provided they are clinically stable (i.e. without evidence of progression by imaging for at least four weeks prior to enrollment and any neurologic symptoms have returned to baseline), and have not received steroids (for a total equivalent dose of more than 10 mg of prednisone per day) for at least 7 days prior to enrollment.
4. Uncontrolled blood pressure (Systolic BP>140 mmHg or diastolic BP >90 mmHg) in spite of an optimized regimen of antihypertensive medication.
5. Significant cardiovascular impairment: history of congestive heart failure greater than New York Heart Association (NYHA) Class II, unstable angina, myocardial infarction or stroke within 6 months of the first dose of study drug, or cardiac arrhythmia requiring medical treatment at Screening.
6. Intratumor cavitation, direct invasion of main mediastinal blood vessels by the tumor or exist previous bleeding.
7. Subjects having > 1+ proteinuria on urine dipstick testing unless a 24-hour urine collection for quantitative assessment indicates that the urine protein is <1 g/24 hours.
8. Has received prior investigational agents within 4 weeks prior to allocation.
9. Participants must have recovered from all AEs due to previous therapies to ≤ Grade 1 or baseline. Participants with ≤ Grade 2 neuropathy may be eligible.
10. If participant received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting study treatment. If surgery is needed during treatment, lenvatinib will be withheld for at least 1 week prior to elective surgery and until at least 2 weeks following major surgery and adequate wound healing. The safety of resumption of lenvatinib after resolution of wound healing has not been established.
11. Fraction ejection < 50%.
12. Known history or current evidence of active Hepatitis B (e.g., HBsAg reactive) or C (e.g., HCV RNA [qualitative] is detected) or Human Immunodeficiency Virus (HIV) (HIV-1/2 antibodies).
13. If CT has to be used, known contra-indications for CT with IV contrast.

14. Chronic use of immunosuppressive agents and/or systemic corticosteroids or any use in the last 15 days prior to enrolment:

    a. Daily prednisone at doses up to 10 mg or equivalent doses of any other corticosteroid is allowed for example as replacement therapy.

15. History of interstitial lung disease (ILD) OR pneumonitis (other than COPD exacerbation) that has required oral or IV steroids.
16. Active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (i.e., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment and is allowed.
17. Has received a live vaccine within 30 days prior to the first dose of study drug. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella/zoster (chicken pox), yellow fever, rabies, Bacillus Calmette-Guérin (BCG), and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (e.g., FluMist®) are live attenuated vaccines and are not allowed.
18. Autoimmune disorders requiring immunosuppressive or dedicated treatment.
19. History of any other hematologic or primary solid tumor malignancy, unless in remission for at least 5 years and without specific treatment (as example, not allowed hormonal therapy to replace for breast cancer or hormonal therapy substitution in prostate cancer). pT1-2 prostatic cancer Gleason score < 6, superficial bladder cancer, non-melanomatous skin cancer or carcinoma in situ of the cervix are allowed.
20. Previous allogenic tissue/solid organ transplantation
21. Active infection requiring systemic therapy

22. A WOCBP who has a positive urine pregnancy test within 72 hours prior to allocation (see Appendix 3). If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.

    Note: in the event that 72 hours have elapsed between the screening pregnancy test and the first dose of study treatment, another pregnancy test (urine or serum) must be performed and must be negative in order for subject to start receiving study medication.

23. Has received prior radiotherapy within 2 weeks of start of study treatment.
24. Has severe hypersensitivity (≥ Grade 3) to pembrolizumab and/or any of its excipients; known sensitivity or intolerance to lenvatinib and/or any of its excipients; severe hypersensitivity to monoclonal antibody-containing regimen.
25. Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the subject's participation for the full duration of the study, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.
26. Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.
27. Has an intestinal disease not allowing swallowing pills.
28. Is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through the 6 months after the last dose of trial treatment.

Contacts and Locations

Contacts

Contact: Neus Crespo; +34 623 333 632; neus.crespo@medsir.org

Contact: Alicia García-Sanz; +34 611 261 467; alicia.garcia@medsir.org

Locations

France

Institut Bergonié; Recruiting

Bordeaux, France

Contact: Sophie Cousin

Principal Investigator: Sophie Cousin

Hôpitaux Universitaires de Marseille - Hôpital Nord; Not yet recruiting

Marseille, France

Contact: Laurent Greillier

Principal Investigator: Laurent Greillier

Institut Curie; Not yet recruiting

Paris, France

Contact: Nicolas Girard

Principal Investigator: Nicolas Girard

Centre Hospitalier Universitaire de Toulouse; Recruiting

Toulouse, France

Contact: Laurence Bigay-Game

Principal Investigator: Laurence Bigay-Game

IGR Gustave Roussy; Recruiting

Villejuif, France

Contact: Benjamin Besse

Principal Investigator: Benjamin Besse

Italy

A.O.U. San Luigi Gonzaga; Recruiting

Orbassano, Italy

Contact: Silvia Novello

Principal Investigator: Silvia Novello

Spain

Hospital Clinic i Provincial de Barcelona; Recruiting

Barcelona, Spain, 08036

Contact: Noemí Reguart

Principal Investigator: Noemí Reguart

Complejo Hospitalario Universitario A Coruña (CHUAC); Recruiting

La Coruña, Spain

Contact: Maria Rosario Campelo

Principal Investigator: Maria Rosario Campelo

Hospital Universitario La Paz; Recruiting

Madrid, Spain

Contact: Javier De Castro

Principal Investigator: Javier De Castro

Hospital Universitario Virgen del Rocío; Recruiting

Sevilla, Spain

Contact: Reyes Bernabé

Principal Investigator: Reyes Bernabé

Hospital Universitari i Politècnic La Fe; Recruiting

Valencia, Spain

Contact: Oscar Juan

Principal Investigator: Oscar Juan

Sponsors and Collaborators

MedSIR

Merck Sharp & Dohme LLC

Investigators

• Principal Investigator: Jordi Remon, MD, PhD; HM-CIOCC, Hospital HM Delfos, HM Hospitales, Barcelona (Spain)
• Principal Investigator: Benjamin Besse, MD, PhD; Medical Oncology Department Gustave Roussy, Villejuif (France)

More Information

• Responsible Party: MedSIR
• ClinicalTrials.gov Identifier: NCT04710628
• Other Study ID Numbers: MedOPP341
• First Posted: January 15, 2021
• Last Update Posted: January 19, 2023
• Last Verified: May 2022

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No
• Product Manufactured in and Exported from the U.S.: No

Additional relevant MeSH terms:

Carcinoma; Thymoma; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type; Neoplasms; Neoplasms, Complex and Mixed; Thymus Neoplasms; Thoracic Neoplasms; Neoplasms by Site; Lymphatic Diseases; Pembrolizumab; Lenvatinib; Antineoplastic Agents, Immunological; Antineoplastic Agents; Protein Kinase Inhibitors; Enzyme Inhibitors; Molecular Mechanisms of Pharmacological Action